Intermediate criteria and criteria of substitution;Critères intermédiaires et critères de substitution

Medecine Therapeutique

Volumn 12, Issue 2, 2006, Pages 96-103

  Kassaï, Behrouz ^a   Gueyffier, Francois ^a   Boissel, Jean Pierre ^a  

^a Service de Pharmacologie Clinique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CERIVASTATIN; STATIN; STREPTOKINASE; SUPEROXIDE; TISSUE PLASMINOGEN ACTIVATOR; ZIDOVUDINE;

CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DESCRIPTIVE RESEARCH; HEALTH CARE DELIVERY; HUMAN; MEDICAL LITERATURE; META ANALYSIS; REVIEW; SUBSTITUTION THERAPY; SYSTEMATIC REVIEW; THEORETICAL MODEL;

EID: 33745897659     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Kassai B, Shah NR, Leizorovicz A, Cucherat M, Gueyffier F, Boissel JP. The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. J Clin Epidemiol 2005; 58(10): 1042-51.
2. Boissel JP, Collet JP, Lievre M, Girard P. An effect model for the assessment of drug benefit: example of antiarrhythmic drugs in post-myocardial infarction patients. J Cardiovasc Pharmacol 1993; 22(3): 356-63.
3. The drug approval process. Am J Cardiol 1974; 34(4): 485-6.
4. Reidenberg MM. The drug-approval process. N Engl J Med 1988; 318(24): 1618.
5. Borer JS. t-PA and the principles of drug approval. N Engl J Med 1987; 317(26): 1659-61.
6. Booth W. FDA looks to speed up drug approval process. Science 1988; 241(4872): 1426.
7. Ezzell C. US looking for short cuts to speed drug approval. Nature 1988; 334(6183): 553.
8. Cotton P. Faster drug approval planned; safety questioned. JAMA 1991; 266(21): 2950.
9. Concorde. MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994; 343(8902): 871-81.
10. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321(6): 406-12.
11. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991; 324(8): 509-16.
12. Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet 2005; 366(9483): 409-21.
13. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125(7): 605-13.
14. Boissel JP, Perret L, Bouvenot G, et al. Clinical evaluation: from intermediate to surrogate criteria. Therapie 1997; 52(4): 281-5.
15. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials, summary of a National Institutes of Health workshop. Control Clin Trials 2001; 22(5): 485-502.
16. Gueyffier F, Dib M, Boissel JP. Biological markers: utilization in drug development and approval. Therapie 2001; 56(4): 355-61.
17. Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992; 43(3): 235-44.
18. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8(4): 431-40.
19. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11(2): 167-78.
20. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997; 16(13): 1515-27.
21. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54(3): 1014-29.
22. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1: 49-67.
23. Baker SG. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true end-point. Biostatistics, 2005.
24. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers-are we being naive? J Infect Dis 1997; 175(2): 237-46.
25. Kassai B, Gueyffier F, Cucherat M, Boissel JP. Comparison of bioprosthesis and mechanical valves, a meta-analysis of randomised clinical trials. Cardiovasc Surg 2000; 8(6): 477-83.
26. Leizorovicz A, Boissel JP. Oral anticoagulant in patients surviving myocardial infarction. A new approach to old data. Eur J Clin Pharmacol 1983; 24(3): 333-6.
27. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107(2): 224-33.
28. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318(18): 1162-73.
29. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2(5): 205-7.
30. Boissel JP, Gueyffier F, Boutitie F, Pocock S, Fagard R. Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments. Fundam Clin Pharmacol 2005; 19(5): 579-84.
31. Lensing AW, Hirsh J. 125I-fibrinogen leg scanning: reassessment of its role for the diagnosis of venous thrombosis in post-operative patients. Thromb Haemost 1993; 69(1): 2-7.
32. Lijmer JG, Bossuyt PM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 2002; 21(11): 1525-37.
33. Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999; 282(11): 1061-6.
34. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004; 140(3): 189-202.
35. Dronne MA, Boissel JP, Grenier E. A mathematical model of ion movements in grey matter during a stroke. J Theor Biol 2005.
36. Dronne MA, Boissel JP, Grenier E, et al. Mathematical modelling of an ischemic stroke: an integrative approach. Acta Biotheor 2004; 52(4): 255-72.
37. Boissel JP, Cucherat M, Nony P, Dronne MA, Kassai B, Chabaud S. New approaches in pharmacology: numerical modelling and simulation. Therapie 2005; 60(1): 1-15.
38. Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21(4): 797-804.